Detalles de la búsqueda
1.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 122(3): 411-9, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26540173
2.
Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management.
Curr Opin Urol
; 26(6): 548-55, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27517638
3.
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
Cancer
; 121(2): 311-9, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25236375
4.
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38431761
5.
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Clin Genitourin Cancer
; 21(1): 55-62, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411184
6.
Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury.
Kidney360
; 2(2): 205-214, 2021 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35373014
7.
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Eur J Cancer
; 157: 50-58, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34482189
8.
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
Eur J Cancer
; 135: 203-210, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599410
9.
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
J Immunother Cancer
; 8(1)2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32066646
10.
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
J Immunother Cancer
; 8(1)2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32217762
11.
Correction: A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643308
12.
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Clin Genitourin Cancer
; 15(6): 724-732, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28645482
13.
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
Clin Genitourin Cancer
; 15(3): 403-410.e2, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28254206
14.
Statins and survival outcomes in patients with metastatic renal cell carcinoma.
Eur J Cancer
; 52: 155-62, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26687834
15.
Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective.
Surg Pathol Clin
; 8(4): 657-62, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26612219
16.
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
Clin Cancer Res
; 21(11): 2471-9, 2015 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25724518
17.
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
J Immunother Cancer
; 3: 3, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25767716
Resultados
1 -
17
de 17
1
Próxima >
>>